Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HRH1 | P35367 | 3/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | TEK | Q02763 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7953543 | 0.98 | MEN1 (0.47) | MEN1KMT2ATDP1KDM4EALDH1A1 | |
| SCHEMBL15874989 | 0.96 | MEN1 (0.52) | MEN1KMT2ATDP1KDM4EALDH1A1 | |
| SCHEMBL7603566 | 0.84 | MEN1 (0.44) | MEN1KMT2ATDP1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL7948069 | 0.82 | MEN1 (0.43) | MEN1KMT2ATDP1KDM4EALDH1A1 | |
| SCHEMBL932436 | 0.82 | MEN1 (0.52) | MEN1KMT2ATDP1KDM4EALDH1A1 | |
| Potassium Ion SCHEMBL6312066 | 0.82 | MEN1 (0.43) | MEN1KMT2ATDP1KDM4EALDH1A1 | |
| SCHEMBL6786534 | 0.81 | SMN1; SMN2 (0.57) | MEN1KMT2ATDP1KDM4EALDH1A1 | |
| SCHEMBL22266250 | 0.81 | MEN1 (0.48) | MEN1KMT2ATDP1KDM4EALDH1A1 | |
| SCHEMBL20324990 | 0.81 | MEN1 (0.51) | MEN1KMT2ATDP1KDM4EALDH1A1 | |
| SCHEMBL26384746 | 0.81 | MEN1 (0.48) | MEN1KMT2ATDP1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230078913-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR USE AS PROTEOLYSIS TARGETING CHIMERA LIGANDS | ESSA PHARMA INC. (CA) | 2023-03-16 | — | — | US | claimed |
| CN-114269331-A | Androgen receptor modulators and methods of use as proteolytic targeting chimeric ligands | 埃萨制药股份有限公司 | 2022-04-01 | — | — | CN | claimed |
| EP-3946292-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR USE AS PROTEOLYSIS TARGETING CHIMERA LIGANDS | Essa Pharma, Inc. (CA) | 2022-02-09 | — | — | EP | claimed |
| WO-2020198711-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR USE AS PROTEOLYSIS TARGETING CHIMERA LIGANDS | ESSA PHARMA, INC. (CA) | 2020-10-01 | — | — | WO | claimed |
| EP-3658548-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas Operations, Inc. (US) | 2020-06-03 | — | — | EP | claimed |
| CN-111212835-A | Compounds and methods for targeted degradation of androgen receptors | 阿尔维纳斯运营股份有限公司 | 2020-05-29 | — | — | CN | claimed |
| WO-2019023553-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. (US) | 2019-01-31 | — | — | WO | claimed |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2017-11-16 | — | — | US | claimed |
| EP-0927173-B1 | SUBSTITUTED [2-(1-PIPERAZINYL)ETHOXY]METHYL | UCB SA (BE) | 2002-06-12 | — | — | EP | claimed |
| CN-1072661-C | Novel substituted [2-(1-piperazinyl) ethoxy] methyl | UCB SA (BE) | 2001-10-10 | — | — | CN | claimed |
| US-6140501-A | CHEMICAL INTERMEDIATES | UCB, S.A. (BE) | 2000-10-31 | — | — | US | claimed |
| EP-0927173-A1 | SUBSTITUTED [2-(1-PIPERAZINYL)ETHOXY]METHYL | UCB, S.A. (BE) | 1999-07-07 | — | — | EP | claimed |
| CN-1215395-A | Novel substituted [2-(1-piperazinyl) ethoxy] methyl | UCB SA (BE) | 1999-04-28 | — | — | CN | claimed |
| WO-1997037982-A1 | NOVEL SUBSTITUTED [2-(1-PIPERAZINYL)ETHOXY]METHYL | UCB S.A. (BE) | 1997-10-16 | — | — | WO | claimed |
| US-20230078913-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR USE AS PROTEOLYSIS TARGETING CHIMERA LIGANDS | ESSA PHARMA INC. (CA) | 2023-03-16 | — | — | US | disclosed |
| EP-3658548-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas Operations, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| CN-111212835-A | Compounds and methods for targeted degradation of androgen receptors | 阿尔维纳斯运营股份有限公司 | 2020-05-29 | — | — | CN | disclosed |
| EP-0927173-A1 | SUBSTITUTED [2-(1-PIPERAZINYL)ETHOXY]METHYL | UCB, S.A. (BE) | 1999-07-07 | — | — | EP | disclosed |
| CN-1215395-A | Novel substituted [2-(1-piperazinyl) ethoxy] methyl | UCB SA (BE) | 1999-04-28 | — | — | CN | disclosed |
| WO-1997037982-A1 | NOVEL SUBSTITUTED [2-(1-PIPERAZINYL)ETHOXY]METHYL | UCB S.A. (BE) | 1997-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230078913-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR USE AS PROTEOLYSIS TARGETING CHIMERA LIGANDS | AR, PSMA1, SHBG | MEN1 3186/4885KMT2A 1118/4885TDP1 3714/4885 |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, MDM2, ESRRA | MEN1 2815/4885KMT2A 1478/4885TDP1 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.